TEVA ANNOUNCES FOURTH QUARTER EARNINGS CONFERENCE CALL BUSINESS EDITORS JERUSALEM, ISRAEL--(BUSINESS WIRE)--FEB. 11, 2001-- TEVA PHARMACEUTICAL INDUSTRIES LTD. (NASDAQ:TEVA) TODAY ANNOUNCED IT WILL
--------------------------------------------------------------------------------
JERUSALEM, Israel--(BUSINESS WIRE)--Feb. 11, 2001--
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA.O) today announced
it will release its fourth quarter and full-year 2000 financial
results on Thursday, February 15, 2001. The Company will host a
conference call to be webcast on Thursday, February 15, 2001 at
10:00AM EST to discuss the financial results.
To access the live webcast go to Teva's web site at
www.tevapharm.com and click on the conference call icon. Please login
at least 10 minutes prior to the conference call in order to download
the applicable audio software. A replay of the webcast will be
available within 24 hours at the Company's web site. Alternatively, a
replay of the call will be available until midnight, Eastern Time, on
Feb 21st, 2001. From the USA please dial 1-800-405-2236, for
international callers dial 303-590-3000. The Pass Code to access the
call: "815386".
Teva Pharmaceutical Industries Ltd. headquartered in Israel is
among the top 50 pharmaceutical companies and among the largest
generic pharmaceutical companies in the world. Over 85% of Teva's
sales are outside Israel, mainly in North America and Europe. The
Company develops, manufactures and markets generic and branded human
pharmaceuticals and active pharmaceutical ingredients.
Safe Harbor Statement: This report contains forward-looking
statements, which express the beliefs and expectations of management.
Such statements are based on current expectations and involve a number
of known and unknown risks and uncertainties that could cause the
Company's future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward looking statements. Important factors that
could cause or contribute to such differences include the impact of
pharmaceutical industry regulation, the difficulty of predicting FDA
and other regulatory authority approvals, the regulatory environment
and changes in the health policies and structure of various countries,
acceptance and demand for new pharmaceutical products and new
therapies, the impact of competitive products and pricing, the
availability and pricing of ingredients used in the manufacture of
pharmaceutical products, uncertainties regarding market acceptance of
innovative products newly launched, currently being sold or in
development, the impact of restructuring of clients, reliance on
strategic alliances, fluctuations in currency, exchange and interest
rates, operating results, the impact of the year 2000 issue and
other factors that are discussed in the Company's Annual Report on
Form 20-F and the Company's other filings with the U.S. Securities and
Exchange Commission
--30--cl/ny*
CONTACT: Teva Pharmaceutical Industries Ltd., Jerusalem
Dorit Meltzer, (011) 972-3-926-7554
Director, Investor Relations
Web Site: www.tevapharm.com
KEYWORD: INTERNATIONAL ISRAEL
INDUSTRY KEYWORD: PHARMACEUTICAL CONFERENCE CALLS
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
Copyright 2001, Business Wire |
